Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://worthingtonlibraries.org
Are you over 18 and want to see adult content?
A complete backup of https://blago.ru
Are you over 18 and want to see adult content?
A complete backup of https://licheoptics.com
Are you over 18 and want to see adult content?
A complete backup of https://kbs-frb.be
Are you over 18 and want to see adult content?
A complete backup of https://camperforum.nl
Are you over 18 and want to see adult content?
A complete backup of https://wcbstv.com
Are you over 18 and want to see adult content?
A complete backup of https://boomtron.com
Are you over 18 and want to see adult content?
A complete backup of https://lepotcommun.fr
Are you over 18 and want to see adult content?
A complete backup of https://berezin.com
Are you over 18 and want to see adult content?
A complete backup of https://pixiedustsavings.com
Are you over 18 and want to see adult content?
A complete backup of https://jobstarter.de
Are you over 18 and want to see adult content?
A complete backup of https://mistermoney.nl
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.commercialappeal.com/picture-gallery/sports/nba/grizzlies/2020/02/13/memphis-grizzlies-vs-portland-trai
Are you over 18 and want to see adult content?
A complete backup of www.theguardian.com/australia-news/2020/feb/12/anthony-sampieri-sentenced-to-life-in-jail-for-of-child-in-k
Are you over 18 and want to see adult content?
Text
future
INVESTOR RELATIONS
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the. May 12, 2021. Autolus Therapeutics to Present New OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products. Autolus is applying pattern recognition technology to engineer T cells with that are designed to enhance selectivity for tumour cells, PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company. CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
SCIENTIFIC DATA MANAGEMENT SYSTEM Reset Password. If you know your user email id, please enter it below. User Email Id : We will send you an email immediately with instructions on how to access your account. HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to developfuture
INVESTOR RELATIONS
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the. May 12, 2021. Autolus Therapeutics to Present New OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products. Autolus is applying pattern recognition technology to engineer T cells with that are designed to enhance selectivity for tumour cells, PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company. CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
SCIENTIFIC DATA MANAGEMENT SYSTEM Reset Password. If you know your user email id, please enter it below. User Email Id : We will send you an email immediately with instructions on how to access your account. CORPORATE PRESENTATIONS Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com SITEMAP | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.comACCESSIBILITY
If you are using a desktop PC, then follow these simple instructions: Mozilla Firefox: Go to View in your browser and select Zoom, select Zoom Text Only, then select Zoom In. Internet Explorer: Go to View in your browser and then select Text Size and select the size you require from the drop-down list. Google Chrome: Go to Options (denoted by a COOKIES | AUTOLUS THERAPEUTICS PLC Site performance cookies. This type of cookie remembers your preferences for tools used within our website, so you do not have to reset them each time you visit. Examples include: Disclaimers or notifications which require input (accept or decline). Filtering options for archives, news, case studies, etc. Video/audio streamingspeeds that are
TERMS | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.comWWW.AUTOLUS.COM
Redirecting to https://www.autolus.com/partners/. AUTOLUS THERAPEUTICS PIPELINE CHARTSWEB VIEW Author: Sophie-Marie Steenkamp Created Date: 03/07/2019 04:30:49 Title: Autolus Therapeutics Pipeline charts Subject: Autolus Therapeutics Pipeline chartsSDMS.AUTOLUS.COM
Enter Scientific Data Management System Login Credentials. User Identification: Password Forgot your password? Click here E CAR T OLONG PERSISTENC ALL EAT W-FINIT CD19 CAR LETTERS NATURE MEDICINE grade1–2neurotoxicity(ExtendedDataFig.6andSupplementary Tables3and6),includingdysarthria,paresthesiaandsomnolence SCIENTIFIC DATA MANAGEMENT SYSTEM Reset Password. If you know your user email id, please enter it below. User Email Id : We will send you an email immediately with instructions on how to access your account. HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to developfuture
INVESTOR RELATIONS
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the. May 12, 2021. Autolus Therapeutics to Present New OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products. Autolus is applying pattern recognition technology to engineer T cells with that are designed to enhance selectivity for tumour cells, PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company. CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
CORPORATE PRESENTATIONS View or download the latest corporate presentations from AutolusTherapeutics
HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to developfuture
INVESTOR RELATIONS
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the. May 12, 2021. Autolus Therapeutics to Present New OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products. Autolus is applying pattern recognition technology to engineer T cells with that are designed to enhance selectivity for tumour cells, PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company. CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
CORPORATE PRESENTATIONS View or download the latest corporate presentations from AutolusTherapeutics
ABSTRACTS & PUBLICATIONS View abstract. AUTO6NG overcomes immune suppressive mechanisms in the TME and demonstrate preclinical anti-tumor activity in GD2-expressing solid tumors. Margarida Neves, Lukas Stanczuk, Alireza Alavi, Meggan Czapiga, Rebecca Moore, Frederick Vargas and Muhammad A. Al-Hajj. DOI: 10.1158/1538-7445.AM2020-2661 Published August 2020. View abstract. SITEMAP | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com TERMS | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com COOKIES | AUTOLUS THERAPEUTICS PLC Site performance cookies. This type of cookie remembers your preferences for tools used within our website, so you do not have to reset them each time you visit. Examples include: Disclaimers or notifications which require input (accept or decline). Filtering options for archives, news, case studies, etc. Video/audio streamingspeeds that are
WWW.AUTOLUS.COM
Redirecting to https://www.autolus.com/partners/. AUTOLUS THERAPEUTICS PIPELINE CHARTSWEB VIEW Author: Sophie-Marie Steenkamp Created Date: 03/07/2019 04:30:49 Title: Autolus Therapeutics Pipeline charts Subject: Autolus Therapeutics Pipeline charts DOWNLOAD FILE :: AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com E CAR T OLONG PERSISTENC ALL EAT W-FINIT CD19 CAR LETTERS NATURE MEDICINE grade1–2neurotoxicity(ExtendedDataFig.6andSupplementary Tables3and6),includingdysarthria,paresthesiaandsomnolenceSDMS.AUTOLUS.COM
Enter Scientific Data Management System Login Credentials. User Identification: Password Forgot your password? Click here SCIENTIFIC DATA MANAGEMENT SYSTEM Reset Password. If you know your user email id, please enter it below. User Email Id : We will send you an email immediately with instructions on how to access your account. HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL. Dr Wendy Osborne of Newcastle upon Tyne Hospitals NHS Foundation Trust discusses AUTO3 data, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory DLBCL patients, presented during the American Society of Clinical Oncology (ASCO) Annual OVERVIEW | AUTOLUS THERAPEUTICS PLC About us. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.INVESTOR RELATIONS
Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com OVERVIEW | AUTOLUS THERAPEUTICS PLC A personalised treatment. Our next-generation T cell programming technologies allow us to tailor our therapies to address the specific cancer we are targeting and introduce new programming modules into a patient’s T cells to give those T cells improved properties to better recognise cancer cells and overcome fundamental cancer defencemechanisms.
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 PIPELINE | AUTOLUS THERAPEUTICS PLC A programmed T cell therapy targeting GD2 in development for the treatment of neuroblastoma. A Phase 1 clinical trial with AUTO6 is being sponsored and conducted by Cancer Research UK, or CRUK, and preliminary data has shown initial anti-tumor activity in this solidtumor indication.
CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company.BOARD OF DIRECTORS
BOARD OF DIRECTORS. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T-cell therapy company. CORPORATE PRESENTATIONS View or download the latest corporate presentations from AutolusTherapeutics
HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL. Dr Wendy Osborne of Newcastle upon Tyne Hospitals NHS Foundation Trust discusses AUTO3 data, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory DLBCL patients, presented during the American Society of Clinical Oncology (ASCO) Annual OVERVIEW | AUTOLUS THERAPEUTICS PLC About us. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.INVESTOR RELATIONS
Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com OVERVIEW | AUTOLUS THERAPEUTICS PLC A personalised treatment. Our next-generation T cell programming technologies allow us to tailor our therapies to address the specific cancer we are targeting and introduce new programming modules into a patient’s T cells to give those T cells improved properties to better recognise cancer cells and overcome fundamental cancer defencemechanisms.
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 PIPELINE | AUTOLUS THERAPEUTICS PLC A programmed T cell therapy targeting GD2 in development for the treatment of neuroblastoma. A Phase 1 clinical trial with AUTO6 is being sponsored and conducted by Cancer Research UK, or CRUK, and preliminary data has shown initial anti-tumor activity in this solidtumor indication.
CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company.BOARD OF DIRECTORS
BOARD OF DIRECTORS. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T-cell therapy company. CORPORATE PRESENTATIONS View or download the latest corporate presentations from AutolusTherapeutics
ABSTRACTS & PUBLICATIONS Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Luca Biasco, Natalia Izotova, Christine Rivat, Sara Ghorashian, Rachel Richardson, Aleks Guvenel, Rachael Hough, Robert Wynn, Bilyana Popova, Andre Lopes, Martin Pule, Adrian J. Thrasher, Persis J. AmroliaACCESSIBILITY
Accessibility. AutolusLimited ("Autolus”) seeks to make its website as accessible as possible and has built the site with the following inmind:
TERMS | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com COOKIES | AUTOLUS THERAPEUTICS PLC Cookie policy. Introduction. Autolus Limited ("Autolus") respects your privacy and is committed to protecting your personal data. This cookie notice will inform youWWW.AUTOLUS.COM
Redirecting to https://www.autolus.com/partners/. AUTOLUS THERAPEUTICS PIPELINE CHARTSWEB VIEW Author: Sophie-Marie Steenkamp Created Date: 03/07/2019 04:30:49 Title: Autolus Therapeutics Pipeline charts Subject: Autolus Therapeutics Pipeline charts DOWNLOAD FILE :: AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.comWWW.AUTOLUS.COM
Redirecting to
https://www.autolus.com/about-us/board-directors/dr-martin-murphy/.SDMS.AUTOLUS.COM
Enter Scientific Data Management System Login Credentials. User Identification: Password Forgot your password? Click here SCIENTIFIC DATA MANAGEMENT SYSTEM If you know your user email id, please enter it below. User Email Id : HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to developfuture
OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company. SITEMAP | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com AGM | AUTOLUS THERAPEUTICS PLC Annual General Meeting 2020. AGM is scheduled to be held at Autolus headquarters in White City at 1.00 pm BST (8.00 am EDT) on Thursday, June 18, 2020. Attendance in person is not permitted. Show all.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
E CAR T OLONG PERSISTENC ALL EAT W-FINIT CD19 CAR LETTERS NATURE MEDICINE grade1–2neurotoxicity(ExtendedDataFig.6andSupplementary Tables3and6),includingdysarthria,paresthesiaandsomnolence HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to developfuture
OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company. SITEMAP | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com AGM | AUTOLUS THERAPEUTICS PLC Annual General Meeting 2020. AGM is scheduled to be held at Autolus headquarters in White City at 1.00 pm BST (8.00 am EDT) on Thursday, June 18, 2020. Attendance in person is not permitted. Show all.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
E CAR T OLONG PERSISTENC ALL EAT W-FINIT CD19 CAR LETTERS NATURE MEDICINE grade1–2neurotoxicity(ExtendedDataFig.6andSupplementary Tables3and6),includingdysarthria,paresthesiaandsomnolence SITEMAP | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com CORPORATE PRESENTATIONS Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.comACCESSIBILITY
If you are using a desktop PC, then follow these simple instructions: Mozilla Firefox: Go to View in your browser and select Zoom, select Zoom Text Only, then select Zoom In. Internet Explorer: Go to View in your browser and then select Text Size and select the size you require from the drop-down list. Google Chrome: Go to Options (denoted by a TERMS | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com COOKIES | AUTOLUS THERAPEUTICS PLC Site performance cookies. This type of cookie remembers your preferences for tools used within our website, so you do not have to reset them each time you visit. Examples include: Disclaimers or notifications which require input (accept or decline). Filtering options for archives, news, case studies, etc. Video/audio streamingspeeds that are
WWW.AUTOLUS.COM
Redirecting to https://www.autolus.com/partners/. AUTOLUS THERAPEUTICS PIPELINE CHARTSWEB VIEW Author: Sophie-Marie Steenkamp Created Date: 03/07/2019 04:30:49 Title: Autolus Therapeutics Pipeline charts Subject: Autolus Therapeutics Pipeline chartsSDMS.AUTOLUS.COM
Enter Scientific Data Management System Login Credentials. User Identification: Password Forgot your password? Click here E CAR T OLONG PERSISTENC ALL EAT W-FINIT CD19 CAR LETTERS NATURE MEDICINE grade1–2neurotoxicity(ExtendedDataFig.6andSupplementary Tables3and6),includingdysarthria,paresthesiaandsomnolence SCIENTIFIC DATA MANAGEMENT SYSTEM Reset Password. If you know your user email id, please enter it below. User Email Id : We will send you an email immediately with instructions on how to access your account. HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to developfuture
INVESTOR RELATIONS
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the. May 12, 2021. Autolus Therapeutics to Present New OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
OVERVIEW | AUTOLUS THERAPEUTICS PLC TECHNOLOGY. Autolus is applying its broad array of T cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and attack and kill these cells. CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
CORPORATE PRESENTATIONS View or download the latest corporate presentations from AutolusTherapeutics
HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to developfuture
INVESTOR RELATIONS
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the. May 12, 2021. Autolus Therapeutics to Present New OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
OVERVIEW | AUTOLUS THERAPEUTICS PLC TECHNOLOGY. Autolus is applying its broad array of T cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and attack and kill these cells. CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
CORPORATE PRESENTATIONS View or download the latest corporate presentations from AutolusTherapeutics
OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
SITEMAP | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com TERMS | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com COOKIES | AUTOLUS THERAPEUTICS PLC Site performance cookies. This type of cookie remembers your preferences for tools used within our website, so you do not have to reset them each time you visit. Examples include: Disclaimers or notifications which require input (accept or decline). Filtering options for archives, news, case studies, etc. Video/audio streamingspeeds that are
WWW.AUTOLUS.COM
Redirecting to https://www.autolus.com/partners/. AUTOLUS THERAPEUTICS PIPELINE CHARTSWEB VIEW Author: Sophie-Marie Steenkamp Created Date: 03/07/2019 04:30:49 Title: Autolus Therapeutics Pipeline charts Subject: Autolus Therapeutics Pipeline chartsWWW.AUTOLUS.COM
Redirecting to
https://www.autolus.com/investor-relations/news-events/events./.WWW.AUTOLUS.COM
Redirecting to
https://www.autolus.com/about-us/board-directors/dr-martin-murphy/.SDMS.AUTOLUS.COM
Enter Scientific Data Management System Login Credentials. User Identification: Password Forgot your password? Click here SCIENTIFIC DATA MANAGEMENT SYSTEM Reset Password. If you know your user email id, please enter it below. User Email Id : We will send you an email immediately with instructions on how to access your account. HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to developfuture
INVESTOR RELATIONS
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the. May 12, 2021. Autolus Therapeutics to Present New OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products. Autolus is applying pattern recognition technology to engineer T cells with that are designed to enhance selectivity for tumour cells, PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
SCIENTIFIC DATA MANAGEMENT SYSTEM Reset Password. If you know your user email id, please enter it below. User Email Id : We will send you an email immediately with instructions on how to access your account. HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to developfuture
INVESTOR RELATIONS
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the. May 12, 2021. Autolus Therapeutics to Present New OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cellproduct
OVERVIEW | AUTOLUS THERAPEUTICS PLC Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products. Autolus is applying pattern recognition technology to engineer T cells with that are designed to enhance selectivity for tumour cells, PIPELINE | AUTOLUS THERAPEUTICS PLC PIPELINE. Autolus is developing next-generation, programmed T cell therapies for the treatment of hematological malignances and solid tumors. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that aredesigned to better
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company.BOARD OF DIRECTORS
Dr Martin Murphy. Chairman of the Board of Directors. Martin Murphy was appointed as Chairman of the Board of Directors of Autolus in April 2021. He is the Chief Executive Officer of Syncona Limited. Previously, he was a Partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcareinvestments.
SCIENTIFIC DATA MANAGEMENT SYSTEM Reset Password. If you know your user email id, please enter it below. User Email Id : We will send you an email immediately with instructions on how to access your account. SITEMAP | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.comACCESSIBILITY
If you are using a desktop PC, then follow these simple instructions: Mozilla Firefox: Go to View in your browser and select Zoom, select Zoom Text Only, then select Zoom In. Internet Explorer: Go to View in your browser and then select Text Size and select the size you require from the drop-down list. Google Chrome: Go to Options (denoted by a TERMS | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com COOKIES | AUTOLUS THERAPEUTICS PLC Site performance cookies. This type of cookie remembers your preferences for tools used within our website, so you do not have to reset them each time you visit. Examples include: Disclaimers or notifications which require input (accept or decline). Filtering options for archives, news, case studies, etc. Video/audio streamingspeeds that are
WWW.AUTOLUS.COM
Redirecting to https://www.autolus.com/partners/.WWW.AUTOLUS.COM
Redirecting to
https://www.autolus.com/investor-relations/news-events/events./. AUTOLUS THERAPEUTICS PIPELINE CHARTSWEB VIEW Author: Sophie-Marie Steenkamp Created Date: 03/07/2019 04:30:49 Title: Autolus Therapeutics Pipeline charts Subject: Autolus Therapeutics Pipeline chartsWWW.AUTOLUS.COM
Redirecting to
https://www.autolus.com/about-us/board-directors/dr-martin-murphy/.SDMS.AUTOLUS.COM
Enter Scientific Data Management System Login Credentials. User Identification: Password Forgot your password? Click here SCIENTIFIC DATA MANAGEMENT SYSTEM Reset Password. If you know your user email id, please enter it below. User Email Id : We will send you an email immediately with instructions on how to access your account. HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL. Dr Wendy Osborne of Newcastle upon Tyne Hospitals NHS Foundation Trust discusses AUTO3 data, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory DLBCL patients, presented during the American Society of Clinical Oncology (ASCO) Annual OVERVIEW | AUTOLUS THERAPEUTICS PLC About us. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.INVESTOR RELATIONS
Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com OVERVIEW | AUTOLUS THERAPEUTICS PLC TECHNOLOGY. Autolus is applying its broad array of T cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and attack and kill these cells. PIPELINE | AUTOLUS THERAPEUTICS PLC A programmed T cell therapy targeting GD2 in development for the treatment of neuroblastoma. A Phase 1 clinical trial with AUTO6 is being sponsored and conducted by Cancer Research UK, or CRUK, and preliminary data has shown initial anti-tumor activity in this solidtumor indication.
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company.BOARD OF DIRECTORS
BOARD OF DIRECTORS. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T-cell therapy company. SCIENTIFIC DATA MANAGEMENT SYSTEM If you know your user email id, please enter it below. User Email Id : HOME | AUTOLUS THERAPEUTICS PLCABOUT USTECHNOLOGYPIPELINEINVESTOR RELATIONSCAREERSCONTACT US Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL. Dr Wendy Osborne of Newcastle upon Tyne Hospitals NHS Foundation Trust discusses AUTO3 data, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory DLBCL patients, presented during the American Society of Clinical Oncology (ASCO) Annual OVERVIEW | AUTOLUS THERAPEUTICS PLC About us. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.INVESTOR RELATIONS
Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com OVERVIEW | AUTOLUS THERAPEUTICS PLC TECHNOLOGY. Autolus is applying its broad array of T cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and attack and kill these cells. PIPELINE | AUTOLUS THERAPEUTICS PLC A programmed T cell therapy targeting GD2 in development for the treatment of neuroblastoma. A Phase 1 clinical trial with AUTO6 is being sponsored and conducted by Cancer Research UK, or CRUK, and preliminary data has shown initial anti-tumor activity in this solidtumor indication.
CONTACT US | AUTOLUS THERAPEUTICS PLC Media contact. JW Communications. Julia Wilson Tel: +44 (0)7818 430877 Email: j.wilson@autolus.com Contact details for clinical trials information. Tel: +44 (0)1483 920748 CAREERS | AUTOLUS THERAPEUTICS PLC CAREERS. Autolus is an exciting, rapidly expanding, ambitious and well financed biotechnology company seeking to develop and commercialise the next generation of engineered T-cell therapies for haematological malignancies and solid tumours.EXECUTIVE TEAM
EXECUTIVE TEAM. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T cell therapy company.BOARD OF DIRECTORS
BOARD OF DIRECTORS. We share a passion for delivering new treatments which offer substantial benefits for patients. Drawing upon our depth of experience and diversity of skills, Autolus is committed to building a leading T-cell therapy company. SCIENTIFIC DATA MANAGEMENT SYSTEM If you know your user email id, please enter it below. User Email Id : SITEMAP | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.comACCESSIBILITY
Accessibility. AutolusLimited ("Autolus”) seeks to make its website as accessible as possible and has built the site with the following inmind:
TERMS | AUTOLUS THERAPEUTICS PLC Contact us. Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ. Email: contact@autolus.com COOKIES | AUTOLUS THERAPEUTICS PLC Cookie policy. Introduction. Autolus Limited ("Autolus") respects your privacy and is committed to protecting your personal data. This cookie notice will inform youWWW.AUTOLUS.COM
Redirecting to https://www.autolus.com/partners/.WWW.AUTOLUS.COM
Redirecting to
https://www.autolus.com/investor-relations/news-events/events./. AUTOLUS THERAPEUTICS PIPELINE CHARTSWEB VIEW Author: Sophie-Marie Steenkamp Created Date: 03/07/2019 04:30:49 Title: Autolus Therapeutics Pipeline charts Subject: Autolus Therapeutics Pipeline chartsWWW.AUTOLUS.COM
Redirecting to
https://www.autolus.com/about-us/board-directors/dr-martin-murphy/.SDMS.AUTOLUS.COM
Enter Scientific Data Management System Login Credentials. User Identification: Password Forgot your password? Click here SCIENTIFIC DATA MANAGEMENT SYSTEM If you know your user email id, please enter it below. User Email Id :__ __
* About us
* Overview
* Executive Team
* Board of Directors* Technology
* Overview
* Abstracts & Publications* Pipeline
* Investor relations* News and events
* Press releases
* Events
* AGM
* Stock Information
* Stock Quote & Chart * Historical Price Lookup * Investment Calculator* Analyst Coverage
* Financial information* SEC filings
* Quarterly Earnings * Corporate Governance * Documents & Charters * Committee Composition * Corporate presentations * Investor Resources* Investor FAQs
* Investor Contacts
* Email Alerts
* Careers
* Contact Us
FOCUSED ON THE DEVELOPMENT OF PRECISELY TARGETED, CONTROLLED AND HIGHLY ACTIVE T CELL THERAPIES THAT ARE DESIGNED TO OFFER CANCER PATIENTS SUBSTANTIAL BENEFITS OVER EXISTING STANDARD OF CARE. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.ABOUT US
Autolus is a biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer.TECHNOLOGY
We are applying our broad array of T cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and attack and kill thesecells.
------------------------- Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL Dr Wendy Osborne of Newcastle upon Tyne Hospitals NHS Foundation Trust discusses AUTO3 data, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory DLBCL patients, presented during the American Society of Clinical Oncology (ASCO) Annual Meeting – courtesy of theLymphoma Hub.
Find out more
-------------------------STOCK QUOTE
NEWS
PRESENTATION
Autolus Corporate Presentation – March 2021EVENTS
SITE MAP
* About us
* Overview
* Executive Team
* Board of Directors* Technology
* Overview
* Abstracts & Publications* Pipeline
* Investor relations* News and events
* Stock Information
* Financial information * Corporate Governance * Corporate presentations * Investor Resources* Careers
* Contact Us
CONTACT US
Autolus Therapeutics plc Forest House, 58 Wood Lane White City, London, W12 7RZ Email: contact@autolus.comPrivacy | Terms
| Cookies
| Accessibility
| Sitemap
| Search
Copyright © 2021 Autolus . __Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0